Efficacy and Safety of Avatrombopag in Cancer Patients With Thrombocytopenia
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of Avatrombopag in patients with thrombocytopenia induced
by targeted therapy and immunotherapy combination treatment, and provide evidence-based
medication for the clinical use of Avatrombopag in patients with PC ≤50×109/L